Pathology and Microbiology; Haematology/Oncology
Cyclosporin is used as an immunosuppressive agent in the management of a variety of autoimmune disorders1 and in patients of organ transplant to suppress host immunity and prevent rejection.2 It is now well established that acquired aplastic anemia is secondary to immune mediated destruction of stem cells in the bone marrow3 and hence Cyclosporin is used as a first line immunosuppressive drug alone or in combination with anti lymphocyte globulin in the management of aplastic anemia.1 Rhabdomyolysis is a rare side effect of Cyclosporin.4 Here we describe a case of fatal rhabdomyolysis in a young patient who received cyclosporin for treatment of aplastic anemia.
Publication ( Name of Journal)
Journal of Pakistan Medical Association
(2003). Cyclosporin induced fatal rhabdomyolysis in a young patient with acquired aplastic anemia: a case report. Journal of Pakistan Medical Association, 53(7).
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/565